Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Cancer immunotherapy Stories

2011-10-31 07:00:00

PORTLAND, Ore., Oct. 31, 2011 /PRNewswire/ -- AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer. "We are very pleased to collaborate with MedImmune to advance our OX40 agonist programs," said AgonOx CEO Llew...

2011-10-25 15:00:00

CARLSBAD, Calif., Oct. 25, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ:LIFE) today announced that the company has signed an agreement with GlaxoSmithKline Biologicals S.A. (GSK) to develop a diagnostic to be used as a companion test with a GSK candidate cancer immunotherapy. Specifically, Life will develop a qPCR-based molecular diagnostic assay for GSK's MAGE-A3 cancer immunotherapy candidate designed to identify patients likely to benefit from the immunotherapy. MAGE-A3...

2011-10-06 08:30:00

WORCESTER, Mass. and TORONTO, Oct. 6, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (www.generex.com) (OTCBB: GNBT) wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com), today announced that the Company will be present at the Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, October 6, 2011 at the New York Academy of Medicine in New York City. The single-day conference event unites key opinion leaders, industry executives, and...

2011-10-04 07:30:00

BETHESDA, Md., Oct. 4, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it will be presenting at the second annual Cancer Immunotherapy: A Long-Awaited Reality Conference on Thursday, October 6, at the New York Academy of Medicine in New York City. The single-day conference unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of...

2011-10-03 07:00:00

GAITHERSBURG, Md., Oct. 3, 2011 /PRNewswire/ -- MedImmune, the global biologics arm of AstraZeneca, today announced execution of an in-licensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody. Under the terms of this agreement, MedImmune will assume global development rights to tremelimumab and Pfizer will retain the rights to use tremelimumab with specified types of combination therapies. MedImmune plans to explore tremelimumab in a number of...

2011-09-30 03:00:00

BLUE BELL, Pa., Sept. 30, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that scientists, advisors and collaborators of the company will make presentations at multiple scientific conferences: 5th( )Vaccine Global CongressOctober 2-5Seattle, WA Marriott Waterfront Hotel PresentationsDavid Weiner, Ph.D. University of Pennsylvania "Robust DNA vaccine +/- protein...

2011-09-21 08:30:00

WORCESTER, Mass. and TORONTO, Sept. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (OTCBB: GNBT) (www.generex.com) wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), today announced that its lead drug candidate AE37, a novel HER-2/neu-targeted vaccine currently in Phase II development for the treatment of breast cancer, is featured in the October 2011 issue of Scientific American, in a story titled "A New Ally Against Cancer" by Eric von Hofe, Ph.D.,...

2011-09-19 22:14:15

Regulatory protein represents potential drug target Medulloblastomas constitute the most frequent class of malignant childhood brain tumor. Tumors of this type arise due to the uncontrolled proliferation of immature nerve cells in the developing brain, and there is no targeted treatment available. A research team based at LMU℠s Center for Neuropathology and Prion Research and led by Privatdozent Dr. Ulrich Schüller has now demonstrated that the regulatory protein FoxM1...

2011-09-19 10:34:00

WORCESTER, Mass. and TORONTO, Sept. 19, 2011 /PRNewswire/ -- Generex Biotechnology Corporation's (OTCBB: GNBT) (www.generex.com) wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), today announced that AE37, a novel HER-2/neu-targeted vaccine for the treatment of breast, prostate, and other cancers, is reviewed in the September 2011 issue of Expert Opinion on Biological Therapy, a peer-reviewed, international journal publishing review articles and original papers on...

2011-09-16 11:28:21

Some of the newest therapies in the war on cancer remove the brakes cancer puts on the immune system, Georgia Health Sciences University researchers report. These immunotherapies, such as CTLA4, strengthen the immune system's attack on cancer by keeping apart two proteins that prevent key immune cells called T cells from activating. Research featured on the cover of the Journal of Immunology suggests that these therapies also keep tumors from benefitting from IDO, an enzyme used by...